Tilpotide/Tisiparatide (Mufengda) indications and main treatment range of diseases

Tirpotide/tirzepatide (Tirzepatide) is a "dual-target" anti-hyperglycemic and weight-loss drug that acts on both GIP and GLP-1 receptors. Therefore, it has a wider and stronger ability to improve metabolism in clinical practice. Currently, Tirzepatide's core indications are mainly focused on the treatment of type 2 diabetes, and is suitable for adult patients who cannot achieve good blood sugar control through diet and exercise. Because it can significantly reduce fasting and postprandial blood sugar while improving insulin sensitivity, it is regarded as one of the most important new drugs in the treatment of diabetes in recent years. It is often used in diabetic patients who have insufficient basic treatment, are intolerant to traditional oral hypoglycemic drugs, or have a higher body weight.

With the publication of a large number of clinical study results, Tirzepatide's effectiveness in the treatment of obesity or overweight-related diseases has also been recognized. Studies have shown that it can significantly reduce body fat proportion, reduce appetite, and improve the risk of metabolic syndrome, so it is approved for the treatment of obese patients with excessive BMI, including those with type 2 diabetes, dyslipidemia, fatty liver, or hypertension. Tirzepatide is also considered an effective long-term weight management option for people who do not have diabetes but are at risk for obesity or metabolic risk, helping to reduce the risk of chronic disease.

Additionally, Tirzepatide has shown positive signs in studies for the treatment of non-alcoholic fatty liver disease (NAFLD/NASH). Multiple trials have shown that the drug can reduce liver fat content, improve liver inflammation and the risk of fibrosis, so further expansion of indications as a treatment for fatty liver is being promoted in many countries. Although this indication has not yet been fully approved, the clinical community generally believes that Tirzepatide is an important treatment candidate for fatty liver and metabolic liver diseases in the future.
Taken together, Tirzepatide's therapeutic scope is expanding from a "hyperglycemic drug" to a "comprehensive metabolism-improving drug." Its currently officially approved indications include type 2 diabetes and obesity/overweight management, and has shown potential value in areas such as fatty liver and cardiometabolic diseases. As the global demand for the treatment of metabolic diseases continues to grow, the indications of Tirzepatide are expected to continue to expand in the next few years, bringing new options to more patients with metabolic diseases.
Reference: https://pubmed.ncbi.nlm.nih.gov/36251836/